The FDA is to review Sanofi/Regeneron's Dupixent as a treatment for asthma, a new use that could more than double its sales following its previous approval for eczema. Analysts predict peak annual ...

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

Dupixent dosages for asthma in children Dupixent is also prescribed ... approves a medication, it tracks and reviews side effects of the drug. If you develop a side effect while using Dupixent ...

If approved, GSK's depemokimab will be the first ultra-long-acting biologic that requires only one dose every six months.

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor depemokimab in two respiratory indications – asthma with type II inflammation ...

Looking at Q4 on Slide 6, we reported double-digits sales growth for a third consecutive quarter, supported by our key drivers, vaccines Dupixent ... from priority review. We received 14 approvals ...

The FDA has started a priority review of AstraZeneca and Amgen's severe asthma antibody tezepelumab ... Sanofi/Regeneron's IL-4/IL-13 inhibitor Dupixent (dupilumab) and AZ's own IL-5 inhibitor ...

So what you'll see, you ask the marketplace, what you'll see is a substantial overlap in the physicians that treat asthma and are used to the use Dupixent ... to regulatory review and approval ...

Its leading drugs include Lantus for treating diabetes and Dupixent for treating atopic dermatitis, asthma and chronic ... from the FDA and is under review in the U.K. and E.U. Hellweg projects ...